Claims
- 1. A method for treatment of a material of biological origin, such as membranes, skins, blood vessels, heart valves, tendons and ligaments and, in particular, collagen materials, comprising the steps of chemically removing from the material hydrophobic accompanying substances without chemical alteration to the accompanying substances; and subsequently removing non-hydrophobic accompanying substances.
- 2. The method of claim 1, wherein the material is of biological origin, and further comprising the step of disinfecting the material before removal of the hydrophobic accompanying substances.
- 3. The method of claim 1, wherein the hydrophobic accompanying substances are removed using a wash with a water miscible organic solvent.
- 4. The method of claim 3, wherein the water miscible organic solvent is ethyl alcohol or acetone.
- 5. The method of claim 4, wherein the water miscible organic solvent is heated to a temperature above the melting point of lipids to be removed.
- 6. The method of claim 5, wherein the water miscible organic solvent is heated to a temperature above 35° C. for a minimum of 30 minutes.
- 7. The method of claim 6, wherein the residual concentration of the hydrophobic accompanying substances after initial chemical purification is below 1.0% (w/w).
- 8. The method of claim 3, wherein the wash step with water miscible organic solvent is followed by a wash with non-water miscible organic solvent.
- 9. The method of claim 8, wherein the non-water miscible organic solvent is hexane, diethyl ether, chloroform or petroleum benzene.
- 10. The method of claim 1, wherein hydrophobic accompanying substances are removed using a wash with surfactants.
- 11. The method of claim 1, wherein the non-hydrophobic accompanying substances are removed using a solution of hydrogen bond breaking substances.
- 12. The method of claim 11, wherein the solution is a solution of urea.
- 13. The method of claim 1, wherein the non-hydrophobic accompanying substances are removed using an aqueous solution of inorganic salts.
- 14. The method of claim 13, wherein the aqueous solution of inorganic salts is selected from the group consisting of a buffered solution of sodium chloride, potassium chloride, and calcium chloride.
- 15. The method of claim 13, wherein the aqueous solution of inorganic salts, contains an enzyme inhibitor.
- 16. The method of claim 1, wherein the non-hydrophobic accompanying substances are removed using an alkaline solution.
- 17. The method of claim 15, wherein the alkaline solution is selected from the group consisting of sodium hydroxide solution, potassium hydroxide solution, and calcium hydroxide.
- 18. The method of claim 1, wherein non-hydrophobic accompanying substances are removed using an acidic solution.
- 19. The method of claim 18, wherein the acidic solution is selected from the group consisting of hydrochloric acid, sulfuric acid, and acetic acid.
- 20. The method of claim 1, wherein accompanying substances are removed by a process selected from the group consisting of treatment using a solution that removes substances bound through hydrogen bonds, treatment using a solution that removes alkaline sensitive substances, treatment using a solution that removes acid sensitive substances, and any combination thereof.
- 21. The method of claim 1, wherein the material is of biological origin, and further comprising the step of confectioning the material to a membrane, heart valve, or blood vessel.
- 22. The method of claim 1, wherein the nativity of the material of biological origin is adjusted to a value below 95%.
- 23. The method of 22, wherein the nativity of the material of biological origin is adjusted by irradiation with a dose of 5 kGy-50 kGy.
- 24. The method of claim 1, wherein the material is of biological origin, and further comprising processing the material into a collagen solution, collagen fibers, collagen weaves, collagen fleeces or collagen sponges.
- 25. The method of claim 1, wherein the material is of biological origin, and further comprising processing the material into collagen-elastin solutions, collagen-elastin fibers, collagen-elastin weaves, collagen-elastin fleeces or collagen-elastin sponges.
- 26. The method of claim 21, further comprising the step of seeding the confectioned material of biological origin with cells.
- 27. The method of claim 26, further comprising the step of using the material of biological origin for tissue engineering purposes.
- 28. A collagen-elastin product in the form of an insoluble collagen which contains insoluble elastin.
- 29. The collagen-elastin product of claim 28, containing at least 20% (w/w) of insoluble elastin fibers retaining their original fibrillin structure.
- 30. The collagen-elastin product of claim 28, containing at least 60% (w/w) of insoluble elastin fibers retaining their original fibrillin structure.
- 31. The collagen-elastin product of claim 28, showing revascularization after implantation.
- 32. A membrane for tissue engineering produced by the method of claim 1.
- 33. The membrane of claim 32, used for articular cartilage regeneration of MACI®, ACI, or ACT techniques.
- 34. The membrane of claim 32 in the form of a collagen-elastin membrane.
- 35. The membrane of claim 32, containing residues of a marker molecule selected from the group consisting of glucosamine and galactosamine, below 0.5 n/1000 n.
- 36. The membrane of claim 32, having a nativity which is adjusted to a value below 95%.
- 37. The membrane of claim 32, promoting cell adhesion and/or proliferation of seeded cells.
- 38. A product of biological origin obtained from tendons, ligaments, tubular grafts, skins, or membranes for tissue engineering purposes, and produced by the method of claim 1.
- 39. The product of claim 38, containing residues of a marker molecule selected from the group consisting of glucosamine and galactosamine, below 0.5 n/1000 n.
- 40. The product of claim 39, processed into a freeze-dried sponge for tissue engineering purposes.
Priority Claims (1)
Number |
Date |
Country |
Kind |
101 57 182.8 |
Nov 2001 |
DE |
|
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part of prior filed copending PCT International application no. PCT/DE02/04278, filed Nov. 21, 2002, which designated the United States and on which priority is claimed under 35 U.S.C. §120, the disclosure of which is hereby incorporated by reference, and which PCT International application no. PCT/DE02/04278, filed Nov. 21, 2002 claims the priority of German Patent Application, Serial No. 101 57 182.8, filed Nov. 22, 2001, pursuant to 35 U.S.C. 119(a)-(d), the disclosure of which is incorporated herein by reference.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
PCT/DE02/04278 |
Nov 2002 |
US |
Child |
10853766 |
May 2004 |
US |